Research In Brief
This article was originally published in The Rose Sheet
Executive Summary
Researchers link blue-light skin-treatment devices, increasingly being implemented in professional settings and used by consumers at home, to vision problems. Chitosan microparticles show promise as delivery mechanism for green tea extract, the antioxidant benefit of which is typically limited due to poor skin penetration. More research in brief.
You may also be interested in...
FDA Warns Quasar For Lack Of Proper Skin-Care Device Clearance; Firm Cites Mix-Up
An FDA warning letter to Quasar Bio-Tech suggests the marketer of Baby Quasar and Quasar MD lacks correct 510(k) device clearance and is improperly marketing its home-use skin-care device products. Quasar maintains it holds the correct clearances, and that FDA may be confused by its product nomenclature.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.